No open-access location is known for this record yet.
No open-access location is known for this record yet.
Reimbursed by Commercial Health Plans, 2000-2014Prescription drug pricing and changes in prices for existing drugs have been under intense scrutiny recently. 1For anticancer medications, high drug prices have the potential to affect access and adherence to therapies and increase financial burden for patients. [2]3][4][5] Given the rapidly evolving drug pricing landscape, it is important to evaluate recent pricing for anticancer medications.This study's objectives were to estimate changes in reimbursements for orally administered anticancer drugs paid by commercial health plans from 2000 through 2014, focusing on reimbursements during the year of product launch and changes in reimbursements over time.Methods | TruvenHealth MarketScan outpatient prescription drug data from January 1, 2000, through December 31, 2014, were used to identify claims for dispensed orally administered anticancer medications approved in 2000 or after, 6 excluding any claims for which the total paid was $0 or less or greater than $250 000.To ensure comparable estimates over time, only fills for a single month of therapy were included for all products.There were 483 587 drug fills included in this analysis.Because this was a secondary analysis of deidentified health plan claims, this study received an institutional review board waiver from the University of North Carolina at Chapel Hill.Measures.Mean per-fill payments to the pharmacy for a single month of supply of each product were summarized by calendar year (monthly spending).These payments included contributions made by the health plan and patient but do not include rebates received from manufacturers.Analysis.First, mean monthly spending was summarized for products during the year of initial approval from January 1, 2000, through December 31, 2014.Second, for products available since 2011, changes in monthly spending were estimated and productspecific monthly spending was compared between the launch year and 2014.For all analyses, generalized estimating equations with log links and normal distributions were used, and means and 95% CIs are presented.All dollars were inflation adjusted to 2014 US dollars using the medical component of the Consumer Price Index.In sensitivity analyses, the top 5% of spending for each drug was excluded to evaluate the influence of outliers on estimates.There were no substantive differences between these results and the primary analysis.
Loading…
Stored only when both papers are in the corpus — 107 citations exist upstream.
Papers that cite the same references — the relational fallback while embeddings are still backfilling.
Imported from OpenAlex (CC0) — nothing here is generated.